18 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
• Disseminated Mycobacterium ... (HAV) infection ... (HBV) infection ... HIVAIDS #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
• Disseminated Mycobacterium ... (HAV) infection ... (HBV) infection ... HIVAIDS #IDSA #management ... #pharmacology
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
chronic hepatitis C virus ... (HCV) infection ... DAAs #Antivirals #table ... HepC #HepatitisC #Management ... #Pharmacology
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Siltuximab) in COVID19 ... correlate with severe COVID ... respiratory tract infection ... #Pharmacology # ... Management #Medications
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Trypanosomiasis) in HIV-AIDS ... be considered (doses ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
Recommendations for Preventing ... Prevention of VZV ... (Varivax™), 2 doses ... #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
General Management ... increase daily dose ... IsosporaBelli #IDSA #Prevention ... #Treatment #management ... #HIVAIDS #pharmacology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
Aplastic Anemia - Overview ... Idiopathic • Infections ... - HIV • Immune ... B19 • Mycobacteria ... hematology #diagnosis #management
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Achieve a total dose ... Leishmaniasis #Prevention ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
(HSV) Infections ... in HIV-AIDS Treating ... #IDSA #Prevention ... #Treatment #management ... #HIVAIDS #pharmacology